What is Hemopet?
Established in 1991, Hemopet operates as the first private non-profit animal blood bank, providing a vital service to the veterinary community. The company specializes in the distribution of state-of-the-art blood components, specifically focusing on DEA 4 universal donors to mitigate transfusion risks. By prioritizing the health and welfare of its donor population, Hemopet has set the industry benchmark for safety and efficacy in veterinary transfusion medicine. Their comprehensive approach addresses the practical, safety, and affordability challenges inherent in modern veterinary care, positioning them as an indispensable partner for clinics requiring reliable, antigen-tested blood supplies.
How much funding has Hemopet raised?
Hemopet has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Hemopet
PPP
Public-Private Partnership
What's next for Hemopet?
With this recent capital infusion, Hemopet is well-positioned to expand its logistical capabilities and enhance its donor management programs. The organization intends to utilize these funds to further optimize its supply chain, ensuring that its life-saving blood products reach a broader network of veterinary practitioners. As the demand for specialized transfusion medicine grows, Hemopet's strategic focus will likely remain on scaling its operational capacity while upholding the stringent quality controls that define its market reputation. This late-stage financing serves as a catalyst for long-term sustainability, allowing the organization to innovate within the niche of veterinary hematology and continue its mission of providing safe, affordable transfusion solutions.
See full Hemopet company page
